Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

nt activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of July 7, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we o
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Decision Resources Group finds that ... for biologic therapy, only a proportion of ... cite patients, discomfort with biological therapy as ... followed by cost-related issues and payer restrictions. ... Janssen Biotech,s Remicade and AbbVie,s Humira are ...
(Date:9/17/2014)... and SAN JOSE, Calif. , ... has been named as a laureate of The Tech Awards ... applying technology to benefit humanity and spark global change. The ... Innovation, and presented by Applied Materials, Inc., selected Gradian as ... Photo - http://photos.prnewswire.com/prnh/20140917/146680 ...
(Date:9/17/2014)... , Sept. 17, 2014  Lightbeam Health Solutions ... Care Organization (Physician Direct ACO) to deploy the ... in providing better care while reducing costs. ... Physician Direct Accountable Care Organization is the ... (OPNS). The OPNS mission is to be the ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3
... Oct. 13 Allscripts (Nasdaq: ... financial results for the three and nine months ended ... on Monday, November 8, 2010. Allscripts management will host ... earnings and other information at 4:30 PM Eastern Standard ...
... (Nasdaq: STXS ) announced today that the new ... of 2010.  The Company generated new capital orders of $12.2 ... placed during the third quarter of 2009, and a 19% ... the Company,s Niobe® Remote Magnetic Navigation System totaled $8.1 million, ...
Cached Medicine Technology:Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 2Allscripts to Announce Third Quarter 2010 Results on November 8, 2010 3Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year 2Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year 3Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year 4
(Date:9/17/2014)... 2014 People who struggle to distinguish between ... http://www.perwickstrom.com and get the answer by reading Per ... out, is that a business plan and a business strategy ... commented Per Wickstrom. “The way I view it is that ... strategy which is part two.” , According to the ...
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... News) -- Positive messages about the health benefits of ... a new study suggests. Although smokers who think ... about the harmful effects of smoking, researchers found smokers ... more from "gain-framed," or positive, messages about how quitting ... using a mix of both types of messages might ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... Washingtonian ... ... was identified as a "Top Therapist" in the July 2009 issue of Washingtonian ... playing in the Washington, DC, area for more than four decades thanks to features like ...
... ... supplier of industrial and technical parts and free CAD images to engineers, ... customers. John Carrier, the company,s President, says the new ReidSupply.com is all about ... on marketing. The new site takes the customer exactly where they want to ...
... LONDON, July 7 Frost & Sullivan has conferred ... (VWS). The "2008 Frost & Sullivan European Pharmaceutical Water ... VWS for its successful strategies that have enabled it ... process water and wastewater solution providers for the pharmaceutical ...
... OAK BROOK, Ill. (July 7, 2009) Using magnetic resonance ... and accurately locate lesions prior to surgery, according to a ... . "Pelvic MRI at 3 Tesla is a ... said the study,s lead author, Nathalie Hottat, M.D., from the ...
... SMOKING CESSATION MAY PROVIDE IMMEDIATE BENEFIT TO HEART ... provides immediate benefits to patients. Researchers from the ... examined specific inflammatory biomarkers associated with cardiovascular disease ... cessation process. Results showed that smoking cessation resulted ...
... Sonitus Medical, Inc., a medical device company developing the ... sound via the teeth, today announced the acceptance for ... SoundBite(TM) hearing system. The article, featuring a preliminary evaluation ... in an upcoming issue of the esteemed Otology ...
Cached Medicine News:Health News:Karen J. Osterle Recognized as a Top Psychotherapist in Washingtonian Magazine 2Health News:Customers Design Reid Supply's New Web Site 2Health News:Customers Design Reid Supply's New Web Site 3Health News:Customers Design Reid Supply's New Web Site 4Health News:Customers Design Reid Supply's New Web Site 5Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 2Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 3Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 4Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 5Health News:MRI accurately depicts deep endometriosis 2Health News:News briefs from the July issue of CHEST 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: